Skip to main content
. Author manuscript; available in PMC: 2021 Oct 12.
Published in final edited form as: Adv Drug Deliv Rev. 2020 Oct 12;160:19–35. doi: 10.1016/j.addr.2020.10.004

Figure 3.

Figure 3

Lymphatic-targeting DDSs for cancer vaccine delivery and immune modulation. A) DDSs enable delivery of adjuvant and/or antigen to APCs, leading to enhanced maturation and expression of co-stimulatory factors, and efficient T cell priming and proliferation. B) Example of LN-targeting cancer vaccine: Aluminum metal organic framework (MOF) design encapsulating model antigen (ZANP), and its mechanism of action. C) Extended release and delivery of ZANPs to DCs in the draining LN; D) Enhanced anti-tumor efficacy of ZANP cancer vaccine DDS over free drug formulations. B-D Reproduced with permission from Ref [114] © 2019 Elsevier1.